Clinical trials: Refractory Soft Tissue Sarcomas
Bone Sarcoma, Soft Tissue Sarcoma
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
This multicenter retrospective study assessed the efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after several lines of TKIs' resistance.
- Conditions
- Bone Sarcoma, Soft Tissue Sarcoma, Refractory Tumor
- Trial name
- NCT06202599
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Peking University People's Hospital
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or…
- Trial name
- NCT06132503
- Testing
- LP-284
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Lantern Pharma Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Sarcoma, Malignant Gastrointestinal Stromal Tumor
Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST
Study Design Type of Study This is an open-label, single arm, prospective, multiple-center phase II study Duration of the Study Period in One Subject Treatment duration is planned for six cycles, unless there is evidence of…
- Trial name
- STS (NCT00359333)
- Testing
- Gemcitabine , Docetaxel
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- National Health Research Institutes, Taiwan
Sarcoma, Synovial
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10
Advanced synovial sarcoma represents an unmet medical need. The gene encoding frizzled homologue 10 (FZD10), a 7-transmenbrane receptor, member of the Wnt signalling receptor family, is overexpressed in SS and is undetectable in…
- Trial name
- SYNFRIZZ (NCT01469975)
- Testing
- OTSA101-DTPA-90Y level 1, OTSA101-DTPA-90Y level 2, OTSA101-DTPA-90Y level 3
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Leon Berard
Sarcoma
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Patients have a type of cancer called sarcoma. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, patients are being asked to…
- Trial name
- NCT00902044
- Testing
- Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
Chronic Myeloproliferative Disorders, Leukemia
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
RATIONALE: A Web site for stem cell transplant health information and support may be effective in helping parents improve their health-related knowledge, skills, and quality of life, which may also improve their children's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00782145
- Testing
- educational intervention, informational intervention, internet-based intervention
- Where
- 6 sites in United States
- Volunteers
- 198 people
- Sponsor
- Tufts Medical Center
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Advanced Soft Tissue Sarcoma
Actinium Therapy for Late-stage Aggressive Sarcomas
The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S.
- Trial name
- ATLAS (NCT07156565)
- Testing
- [Ac 225]RTX-2358, [Cu64]LNTH-1363S
- Where
- 6 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Ratio Therapeutics, Inc.
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
The purpose of this study is to determine if Magnetic Resonance guided High Intensity Focused Ultrasound ablative therapy is safe and feasible for children, adolescents, and young adults with refractory or relapsed solid tumors.
- Conditions
- Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT02076906
- Testing
- Magnetic Resonance High Intensity Focused Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- AeRang Kim
Metastatic Cancer, Sarcoma
Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone
RATIONALE: Radioactive drugs, such as holmium Ho 166 DOTMP, may carry radiation directly to cancer cells and not harm normal cells.
- Trial name
- NCT00006234
- Testing
- peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Pediatric Solid Tumor, Pediatric Lymphoma
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment…
- Conditions
- Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG
- Trial name
- CLOVER-2 (NCT03478462)
- Testing
- CLR 131
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that that may have spread from where it first started to nearby tissue…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT02298959
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 9 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Osteosarcoma
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of Sulfatinib in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed osteosarcoma ( combination…
- Trial name
- NCT05590572
- Testing
- Sulfatinib, Etoposide, Isophosphamide
- Where
- 5 sites in China, South Korea
- Volunteers
- 148 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory).
- Conditions
- Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05286801
- Testing
- Atezolizumab, Biospecimen Collection, Computed Tomography
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma
Cabozantinib With Topotecan-Cyclophosphamide
This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma.
- Conditions
- Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Trial name
- NCT04661852
- Testing
- Cabozantinib, Topotecan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
- Trial name
- NCT02049905
- Testing
- Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 433 people
- Sponsor
- ImmunityBio, Inc.
Sarcoma
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00470275
- Testing
- cytarabine
- Where
- 73 sites in United States, Australia and 2 more
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Soft Tissue Sarcoma
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.
- Trial name
- NCT00717522
- Testing
- Pomalidomide
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celgene